Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02638805 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
A Phase 3 study, sponsored by Intarcia Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 136
- Enrollment target
NCT02638805: Completed Phase 3 study, sponsored by Intarcia Therapeutics.
NCT02638805 is a Phase 3 study that has completed, run by Intarcia Therapeutics. The registered enrollment target is 136 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02638805, a Phase 3 study, has completed, sponsored by Intarcia Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 136 participants
- Enrollment target
Study Summary
A Phase 3b, open-label, randomized, multicenter, safety and tolerability study of ITCA 650 in subjects with Type 2 diabetes taking liraglutide and metformin.
Primary Outcome
Number (percentage) and severity of treatment-emergent AEs (TEAEs) of nausea and/or vomiting over the 26-week treatment period; treatment discontinuation for nausea and/or vomiting; and pattern of nausea and/or vomiting over time.
Interventions
- DRUG Metformin
- DRUG Liraglutide
- DRUG ITCA 650 Osmotic Mini Pump 20/60 mcg/day
- DRUG ITCA 650 Osmotic Mini Pump 60 mcg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-10 |
| Phase | Phase 3 |
What the finished NCT02638805 record still lists
NCT02638805 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 4 interventions - of which Metformin is the first listed.
NCT02638805 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02638805 about?
NCT02638805 is a clinical study titled "Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide". A Phase 3b, open-label, randomized, multicenter, safety and tolerability study of ITCA 650 in subjects with Type 2 diabetes taking liraglutide and metformin.
What is the current status of trial NCT02638805?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2015-12. Estimated completion is 2017-10.
What interventions are being tested in trial NCT02638805?
The interventions under investigation include: Metformin (DRUG), Liraglutide (DRUG), ITCA 650 Osmotic Mini Pump 20/60 mcg/day (DRUG), ITCA 650 Osmotic Mini Pump 60 mcg/day (DRUG).
Who is sponsoring clinical trial NCT02638805?
This trial is sponsored by Intarcia Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02638805's enrollment target sits among peer trials
136 1580th of 2000 higher than 419 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia